

Company registration number 378826 (Republic of Ireland)

ROCKVILLE PHARMACY LIMITED
ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

ROCKVILLE PHARMACY LIMITED

CONTENTS

	Page
Directors' responsibilities statement	1
Directors' declaration	2
Statement of financial position	3 - 4
Notes to the financial statements	5 - 10

ROCKVILLE PHARMACY LIMITED

DIRECTORS' RESPONSIBILITIES STATEMENT

FOR THE YEAR ENDED 31 MARCH 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with Companies Act 2014 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (Generally accepted Accounting Practice in Ireland) issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for that financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:


- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

By order of the board



Grainne Macken
Secretary



Lorcan Macken
Director

14 July 2025

ROCKVILLE PHARMACY LIMITED


DIRECTORS' DECLARATION ON UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

In relation to the financial statements set out on pages 6 to 14:

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgments underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.
- The directors confirm that they have made available to PKF Brenson Lawlor Limited, all the company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all transactions of the company for the year ended 31 March 2025.

By order of the board


Grainne Macken
Secretary


Lorcan Macken
Director

14 July 2025

ROCKVILLE PHARMACY LIMITED

STATEMENT OF FINANCIAL POSITION

AS AT 31 MARCH 2025

		2025		2024	
	Notes	€	€	€	€
Fixed assets					
Tangible assets	5		50,553		55,016
Financial assets	6		-		28,659
			<u>50,553</u>		<u>83,675</u>
Current assets					
Stocks	7	97,928		102,406	
Debtors	8	1,249,171		1,235,165	
Cash at bank and in hand		179,256		223,756	
		<u>1,526,355</u>		<u>1,561,327</u>	
Creditors: amounts falling due within one year	9	<u>(310,004)</u>		<u>(303,775)</u>	
Net current assets			<u>1,216,351</u>		<u>1,257,552</u>
Net assets			<u>1,266,904</u>		<u>1,341,227</u>
Capital and reserves					
Called up share capital presented as equity			121,447		121,447
Profit and loss reserves	10		<u>1,145,457</u>		<u>1,219,780</u>
Total equity			<u>1,266,904</u>		<u>1,341,227</u>

ROCKVILLE PHARMACY LIMITED

STATEMENT OF FINANCIAL POSITION (CONTINUED)

AS AT 31 MARCH 2025

We, as directors of Rockville Pharmacy Limited, state that:

(a) the company is availing itself of the exemption from audit provided for by Chapter 15 of Part 6 of the Companies Act 2014;

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied;

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2), and;

(d) the directors acknowledge the obligations of the company, under the Companies Act 2014, to:


(i) keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities, financial position of the company at the end of its financial year, and of its profit or loss for such a year, and;

(ii) otherwise comply with the provisions of this Act relating to financial statements so far as they are applicable to the company.

(e) The company has relied on the specified exemption contained in section 352 Companies Act 2014; the company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Standard 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland'.

The financial statements were approved by the board of directors and authorised for issue on 14 July 2025 and are signed on its behalf by:



Lorcan Macken
Director

Grainne Macken
Director



ROCKVILLE PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

Company information

Rockville Pharmacy Limited is a limited company domiciled and incorporated in the Republic of Ireland. The registered office is 7 Rockville Road, Newtownpark Avenue, Blackrock, Co. Dublin, A94 RC52 and its company registration number is 378826.

1.1 Accounting convention

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), as adapted by Section 1A of FRS 102, and the requirements of the Companies Act 2014.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention.

1.2 Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings	3% (over 33 years)
Fixtures and fittings	12.5%

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4 Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

ROCKVILLE PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

(Continued)

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.5 Impairment of fixed assets

Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each statement of financial position date. If such indication exists, the recoverable amount of the asset, or the asset's cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

1.6 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7 Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

ROCKVILLE PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

(Continued)

1.9 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.11 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Operating (loss)/profit

	2025	2024
Operating (loss)/profit for the year is stated after charging:	€	€
Depreciation of tangible fixed assets	5,038	6,218

ROCKVILLE PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

3 Directors' remuneration

	2025 €	2024 €
Remuneration for qualifying services	56,678	37,845
Company pension contributions to defined contribution schemes	235,653	104,563
	<u>292,331</u>	<u>142,408</u>

4 Employees

The average monthly number of persons (including directors) employed by the company during the year was:

	2025 Number	2024 Number
Total	<u>9</u>	<u>9</u>

5 Tangible fixed assets

	Leasehold land and buildings €	Fixtures and fittings €	Total €
Cost			
At 1 April 2024	99,550	121,440	220,990
Additions	-	575	575
At 31 March 2025	<u>99,550</u>	<u>122,015</u>	<u>221,565</u>
Depreciation and impairment			
At 1 April 2024	54,550	111,424	165,974
Depreciation charged in the year	3,016	2,022	5,038
At 31 March 2025	<u>57,566</u>	<u>113,446</u>	<u>171,012</u>
Carrying amount			
At 31 March 2025	<u>41,984</u>	<u>8,569</u>	<u>50,553</u>
At 31 March 2024	<u>45,000</u>	<u>10,016</u>	<u>55,016</u>

6 Financial assets

	2025 €	2024 €
Other investments other than loans	<u>-</u>	<u>28,659</u>

ROCKVILLE PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

6	Financial assets	(Continued)	
	Movements in fixed asset investments		Investments
			€
	Cost or valuation		
	At 1 April 2024		28,659
	Disposals		(28,659)
	At 31 March 2025		-
	Carrying amount		
	At 31 March 2025		-
	At 31 March 2024		28,659
7	Stocks	2025	2024
		€	€
	Finished goods and goods for resale	97,928	102,406
8	Debtors	2025	2024
		€	€
	Amounts falling due within one year:		
	Trade debtors	68,064	64,364
	Corporation tax recoverable	37,587	28,791
	Amounts owed by group undertakings	1,132,602	1,132,602
	Prepayments	10,918	9,408
		1,249,171	1,235,165
9	Creditors: amounts falling due within one year	2025	2024
		€	€
		Notes	
	Other borrowings	200,000	200,000
	Trade creditors	84,556	74,548
	Other creditors including tax and social insurance	14,510	19,017
	Accruals	10,938	10,210
		310,004	303,775

ROCKVILLE PHARMACY LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

10 Profit and loss reserves

	2025 €	2024 €
At the beginning of the year	1,219,780	1,154,291
(Loss)/profit for the year	(74,323)	65,489
At the end of the year	<u>1,145,457</u>	<u>1,219,780</u>

11 Related party transactions

The company has identified the following related parties and the transactions between them which are required to be disclosed:

Net balance owed from Rockville Pharmacy Holding Limited, the holding company, at the year end amounted to €732,602 Dr (2024 - €732,602 Dr).

Net balance owed from Macken's Pharmacy Limited, at the year end amounted to €400,000 Dr (2024 - €400,000 Dr).

12 Parent company

Rockville Pharmacy Holding Ltd holds 100% of the issued share capital of Rockville Pharmacy Ltd. Grainne Macken holds 100% of the issued share capital of Rockville Pharmacy Holding Ltd.

13 Approval of financial statements

The directors approved the financial statements on 14 July 2025.